@article{67444b5395a84e68b8de2cec1a585613,
title = "Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).",
author = "Barr, \{Paul M.\} and Brown, \{Jennifer R.\} and Peter Hillmen and Susan OBrien and Barrientos, \{Jacqueline Claudia\} and Reddy, \{Nishitha M.\} and Steven Coutre and Mulligan, \{Stephen P.\} and Ulrich J{\"a}ger and Furman, \{Richard R.\} and Florence Cymbalista and Marco Montillo and Claire Dearden and Tadeusz Robak and Carol Moreno and John Pagel and Burger, \{Jan Andreas\} and Samuel Suzuki and James, \{Danelle Frances\} and Byrd, \{John C.\}",
note = "Background: Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Brutons tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013). Complete or near complete BTK active site occupancy (median 90\%) is achieved at 4 hours and maintained at 24 hours with ibr 420 mg once-daily (OBrien, Lancet Oncology 2013).",
year = "2017",
month = jan,
day = "31",
language = "American English",
journal = "Journal of Clinical Oncology",
}